A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

April 24, 2020

Study Completion Date

October 25, 2021

Conditions

Malignant Neoplasm

Interventions

DRUG

NBM-BMX softgel capsules

Patients will initially receive NBM-BMX orally once a day at 100 mg per day.

Trial Locations (1)

NEXT Oncology, San Antonio

All Listed Sponsors

lead

NatureWise Biotech & Medicals Corporation

INDUSTRY

NCT03726294 - A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter